(-0.93%) 4 964.55 points
(0.41%) 37 931 points
(-2.09%) 15 276 points
(0.82%) $83.41
(0.00%) $1.757
(0.44%) $2 408.50
(1.53%) $28.82
(-1.31%) $942.00
(-0.06%) $0.939
(-0.13%) $11.03
(0.55%) $0.808
(-0.95%) $93.01
Live Chart Being Loaded With Signals
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide...
Stats | |
---|---|
Today's Volume | 20 000.00 |
Average Volume | 31 400.00 |
Market Cap | 135.95M |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -0.330 |
ATR14 | HKD0 (0.00%) |
CANbridge Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
CANbridge Pharmaceuticals Financials
Annual | 2022 |
Revenue: | HKD78.97M |
Gross Profit: | HKD48.89M (61.91 %) |
EPS: | HKD-1.140 |
Q3 | 2023 |
Revenue: | HKD0 |
Gross Profit: | HKD0 (0.00 %) |
EPS: | HKD0 |
Q2 | 2023 |
Revenue: | HKD21.53M |
Gross Profit: | HKD13.34M (61.97 %) |
EPS: | HKD-0.260 |
Q1 | 2023 |
Revenue: | HKD21.53M |
Gross Profit: | HKD13.34M (61.97 %) |
EPS: | HKD-0.260 |
Financial Reports:
No articles found.
CANbridge Pharmaceuticals
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators